These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 15651177)

  • 1. Management of invasive mycoses in hematology patients: current approaches.
    Perfect JR
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):5-14. PubMed ID: 15651177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of newer antifungal therapies in clinical practice: what do the data tell us?
    Perfect JR
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):15-23. PubMed ID: 15651178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Update on therapy of invasive mycoses in hematology and oncology].
    Maschmeyer G; Haas A; Böhme A
    Dtsch Med Wochenschr; 2005 Jun; 130(22):1381-4. PubMed ID: 15915381
    [No Abstract]   [Full Text] [Related]  

  • 4. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections.
    Drug Ther Bull; 2004 Jan; 42(1):5-8. PubMed ID: 14768298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
    Keating G; Figgitt D
    Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The echinocandins.
    Cappelletty D; Eiselstein-McKitrick K
    Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination antifungal therapy: where are we now, and where are we going?
    Marr K
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):24-9. PubMed ID: 15651179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Echinocandins in the management of invasive fungal infections, Part 2.
    Morris MI; Villmann M
    Am J Health Syst Pharm; 2006 Oct; 63(19):1813-20. PubMed ID: 16990627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
    Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
    Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
    Jørgensen KJ; Gøtzsche PC; Dalbøge CS; Johansen HK
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD004707. PubMed ID: 24563222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voriconazole: review of a broad spectrum triazole antifungal agent.
    Kofla G; Ruhnke M
    Expert Opin Pharmacother; 2005 Jun; 6(7):1215-29. PubMed ID: 15957974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of new antifungal agents.
    Kauffman CA
    Curr Opin Microbiol; 2006 Oct; 9(5):483-8. PubMed ID: 16904366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in antifungal chemotherapy.
    Petrikkos G; Skiada A
    Int J Antimicrob Agents; 2007 Aug; 30(2):108-17. PubMed ID: 17524625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic mycoses in the immunocompromised host: an update in antifungal therapy.
    Kontoyiannis DP; Mantadakis E; Samonis G
    J Hosp Infect; 2003 Apr; 53(4):243-58. PubMed ID: 12660121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
    Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
    Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing strategies for the management of invasive fungal infections.
    Rapp RP
    Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.
    Spanakis EK; Aperis G; Mylonakis E
    Clin Infect Dis; 2006 Oct; 43(8):1060-8. PubMed ID: 16983621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.